Remmick So

Sussex Research Laboratories Inc. is a global leader in glycosciences, specializing in advanced glycan synthesis and translational glycobiology to support innovation in medical biotechnology. The glycoscience field focuses on the chemistry and biology of glycan molecules. The biosynthesis, metabolism, and receptor binding properties of glycans make them a key part of many biochemical processes essential to human health.

Our focus and expertise are on the precise design, synthesis, and characterization of complex glycans and glycoconjugates, providing both specialized glycan products and contract research and development services. These synthetic products translate glycomics into practical biomedical applications that advance drug discovery and development. Our technological innovations expand synthetic, disease-relevant glycan libraries for a wide range of biomedical applications, including (i) biomarkers for aberrant glycosylation which is a hallmark of cancer; (ii) biomarkers for metabolic disorders associated with lysosomal storage diseases; (iii) immune targets for vaccine and glycoconjugate vaccine development in oncology and bacterial infection; (iv) ligands of cell surface receptors for the development of targeted drug delivery systems including therapeutic oligonucleotides; (v) characterization and glycoengineering of monoclonal antibodies and other therapeutic proteins; (vi) ligands to investigate the receptor specificity of glycan binding proteins from pathogenic organisms; (vii) glycan probes for diagnostic assay development, for example, ABO Blood group antigens to assess histocompatibility for organ transplantation.

By integrating glycoscience with translational biomedical research, Sussex Research strengthens the foundation for next-generation biologics, precision medicine, and advanced therapeutic development across the global medical biotechnology sector.